Company Updates

The Drive to ‘25

The Drive to ‘25

The drive to 2025 is underway! With 2023 in the rear-view mirror, we at EpicentRx look ahead not only to 2024 but also to 2025 when we expect top-line data from five key EpicentRx clinical trials to read out. For lead FDA Fast Tracked small molecule, RRx-001...

read more
No “Fall” in Activity for EpicentRx After Summer

No “Fall” in Activity for EpicentRx After Summer

A busy Fall “leaves” little to no downtime for EpicentRx Summer slowdown? What summer slowdown? EpicentRx kicked off the Fall season in high gear with continuing preparations for the start of a large Phase 2b follow on study called KEVLARx with nibrozetone (RRx-001)...

read more
Q2 Highlights from ASCO, BIO and beyond

Q2 Highlights from ASCO, BIO and beyond

As you may have noticed, EpicentRx is a company on the move. From the award of FDA Fast Track status for RRx-001 as an anti-oral mucositis agent to invited talks at premier venues like the AD/PD conference in Gothenburg, Sweden and the World Parkinson Congress in...

read more